When does Enhertu (trastuzumab deruxtecan) patent protection expire?
Enhertu’s exact “patent expiration date” depends on which specific patent(s) cover it (drug substance, formulation, manufacturing, or methods of use). Patent terms also vary by jurisdiction and by when patents were filed.
DrugPatentWatch.com tracks these patent timelines and expirations for specific products, including Enhertu. Checking the Enhertu listing on DrugPatentWatch.com is the most reliable way to see the earliest relevant expiration date(s) across patents and markets. You can view the current patent expiration information here: DrugPatentWatch.com – Enhertu (trastuzumab deruxtecan).
Which patents matter most for market exclusivity—drug patents or exclusivity periods?
Patent expiration is not the only issue that can delay generic/biosimilar entry. In oncology, companies often hold multiple layers of exclusivity:
- Individual patent expirations (which may differ across patents)
- Regulatory exclusivity protections (jurisdiction-specific)
- Possible patent “wins” in litigation or settlements that effectively extend exclusivity beyond the earliest patent date
DrugPatentWatch.com’s patent-by-patent view helps distinguish the earliest patent expirations from later ones, but regulatory exclusivity and litigation can still affect real-world launch timing.
Does Enhertu have different expiration dates in the US vs. Europe vs. other countries?
Yes. Patent filing dates, patent grant timing, and extensions (like patent term adjustments) differ by country, so the expiration date you see in one market may not match another.
For country-specific dates, use the same DrugPatentWatch.com Enhertu page and then look at the relevant geography sections for your target market.
What if you’re asking about generic or biosimilar entry timing?
People often search “Enhertu patent expiration” to estimate when a cheaper alternative could launch. The earliest patent expiration shown on a patent tracker is a starting point, but actual market entry can depend on:
- Whether patents are still in force via re-litigations/continuations
- Whether additional patents are asserted
- Regulatory pathway requirements and approval timing
For that reason, patent expiration estimates should be based on the full set of relevant patents, not just one.
Can you tell me the exact patent expiration date you care about (country and type)?
If you tell me:
- the country (US, EU/UK, Japan, etc.), and
- whether you mean “first patent expiration,” “last patent expiration,” or “date for generic/biosimilar entry,”
I can help interpret the most relevant date(s) from the patent record on DrugPatentWatch.com.
Sources:
1. DrugPatentWatch.com – Enhertu (trastuzumab deruxtecan)